Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Adrenergic Neurons: Neurotransmission01:27

Adrenergic Neurons: Neurotransmission

Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A quest for a histaminergic or orexinergic biomarker for sudden infant death syndrome.

Pediatric research·2026
Same author

Endothelin-1 modulates hippocampal and hypothalamic neuronal network activity in mouse primary dissociated cultures and brain slices.

Peptides·2026
Same author

Impaired theory of mind in Parkinson's disease: A systematic review of etiological debates.

Neuroscience and biobehavioral reviews·2026
Same author

Comprehensive microarray analysis for the identification of therapeutic targets within HIF-1α signalling networks in diet-induced obesity via hypothalamic inflammation.

Archives of endocrinology and metabolism·2025
Same author

Comparative analysis of adenosine 1 receptor expression and function in hippocampal and hypothalamic neurons.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2025
Same author

Neuronal HIF-1α expression in mediobasal hypothalamus affects glycolipid metabolism and body weight in mice fed with high-fat diet.

The European journal of neuroscience·2024

Related Experiment Video

Updated: Jun 5, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

L-Dopa activates histaminergic neurons.

Yevgenij Yanovsky1, Sha Li, Boris P Klyuch

  • 1Department of Neurophysiology, Heinrich-Heine-University, D-40001, Dusseldorf, Germany.

The Journal of Physiology
|January 19, 2011
PubMed
Summary

L-Dopa treatment for Parkinson's disease (PD) can be improved by targeting histamine neurons. These neurons, excited by L-Dopa, co-release dopamine and histamine, offering new therapeutic strategies.

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

Related Experiment Videos

Last Updated: Jun 5, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • L-Dopa is a primary Parkinson's disease (PD) treatment, but chronic use causes diminishing efficacy and dyskinesia.
  • Histamine antagonists can delay these L-Dopa side effects by enabling lower dosages.

Purpose of the Study:

  • To investigate the role of histaminergic tuberomamillary nucleus (TMN) neurons in L-Dopa's effects.
  • To explore the mechanisms of L-Dopa action on TMN neurons and their potential for PD therapy.

Main Methods:

  • Patch-clamp recordings from brain slices and single-cell RT-PCR analysis of dopamine receptor expression.
  • Microdialysis in freely moving rats to measure histamine release.
  • Electroencephalography (EEG) recordings to assess wakefulness.
  • Experiments in histamine-deficient mice.

Main Results:

  • Histaminergic TMN neurons are excited by L-Dopa, express Dopa decarboxylase, and dopamine.
  • TMN neurons possess both D1-like and D2-like dopamine receptors.
  • D2 receptor activation increases neuronal firing, histamine release, and wakefulness.
  • Histamine deficiency abolishes the wake-promoting effects of D2 receptor agonists.

Conclusions:

  • Histaminergic TMN neurons can co-release dopamine and histamine following L-Dopa uptake.
  • The interaction between dopaminergic and histaminergic systems suggests novel therapeutic targets for Parkinson's disease.
  • Histamine H3 receptor interactions with dopamine receptors in the striatum may offer new avenues for PD treatment.